NOTTINGHAM, UK – June 4th, 2025 – 4D Medicine Limited, a pioneering developer of advanced biomaterials for orthopaedic and surgical applications, is pleased to announce its participation as an exhibitor at the Orthopaedic Manufacturing & Technology Exposition and Conference (OMTEC) 2025, taking place June 18–19 at the Donald E. Stephens Convention Center in Chicago, Illinois.

Attendees are invited to connect with 4D Medicine at Booth #558, where the company will be showcasing 4Degra®- its innovative bioabsorbable polymer platform that offers unprecedented performance in tissue repair and regeneration. This cutting-edge biomaterial, featuring novel polycarbonate urethane chemistry, is designed to meet the evolving needs of the orthopaedic, spine, and trauma markets. 

4D Medicine will be actively seeking sales channel partners for the Degrafix Interference Screw that delivers improved biocompatibility and more predictable resorption to increase surgeon confidence in long-term procedural success. The DegraFix interference Screw is the first product in a potential portfolio of improved soft tissue fixation devices.

“We are excited to engage with industry leaders and investors at OMTEC 2025,” said Phil Smith, CEO of 4D Medicine Limited. “Our materials offer unique advantages in terms of processibility, biocompatibility, and regenerative potential. We look forward to exploring strategic partnerships that will accelerate commercialization and expand clinical impact.”

Attendees are encouraged to schedule meetings in advance by contacting the 4D Medicine business development team at info@4dmedicine.co.uk.

For more information about 4D Medicine Limited and its novel biomaterial platform, please visit www.4dmedicine.co.uk.

ENDS

NOTTINGHAM, UK. 3rd April, 2025 – 4D Biomaterials Ltd, the materials manufacturing subsidiary of 4D Medicine Ltd, a UK university spin-out company developing next-generation bioresorbable medical devices, today announced it has achieved ISO 13485:2016 certification from The British Standards Institution (BSI). 

This globally recognised quality standard for medical device manufacturing marks a critical milestone in the company’s path to market, demonstrating high quality, low risk and customer-focused manufacturing capability. 

The certification confirms that 4D Biomaterials Ltd operates under a quality management system that meets stringent international regulatory requirements — a core prerequisite for the raw materials used in medical devices seeking regulatory approvals, clinical deployment, and global distribution. As such, certification significantly de-risks the company’s commercial strategy. 

Phil Smith, CEO of parent company, 4D Medicine Ltd commented:

“This achievement is a pivotal moment for our materials manufacturing business. ISO 13485 certification validates its operational systems and sends a clear signal to partners and investors: we are ready to scale. It also reflects the maturity of our technology platform, the discipline of our team, and our commitment to executing a high-quality commercialisation strategy.”

This milestone positions 4D to accelerate the development of commercial partnerships, regulatory approvals, and revenue-generating opportunities as it advances its differentiated product pipeline toward global markets.

ENDS

NOTTINGHAM, UK. March 11th, 2025 – 4D Medicine Ltd, an emerging innovator in the biomaterials and medical device sector, is proud to announce the launch of its newly redesigned corporate website, www.4dmedicine.co.uk.

The site is designed to offer a comprehensive resource for investors, strategic partners, and healthcare professionals, highlighting the company’s groundbreaking 4Degra® bioabsorbable polymer technology and its potential to transform the medical device industry.

The new website offers information on the unique properties of 4Degra®, a next-generation bioabsorbable polymer developed to improve patient outcomes in medical device applications. 4Degra®’s unparalleled versatility and biocompatibility make it an ideal material for a wide range of devices, including those used in musculoskeletal repair, soft tissue regeneration and drug-delivery.

“4Degra® represents the next evolution in bioabsorbable materials, and this website serves as an essential tool to communicate the exciting opportunities that lie ahead for investors and collaborators,” said Phil Smith, CEO of 4D Medicine. 

“We’ve designed the site to not only inform but to also demonstrate the potential impact our technology can have in improving surgical outcomes and improving lives.”

Key features of the new website include:

The launch of this website underscores 4D Medicine’s commitment to transparency, collaboration, and ongoing innovation. The company is poised to lead the way in delivering solutions that enhance patient care and create lasting value for its partners and stakeholders.

ENDS

BOSTON, MA. March 5th, 2025 – Today, protocols.io, a platform that enables academic and industry researchers to record and share up-to-date methods for research, announced that, under eLabNext leadership, its platform is now available for integration with eLabNext’s Digital Lab Platform (DLP), an intuitive and flexible system for collecting, managing, and analyzing laboratory information. 

The seamless connections between protocols.io and the DLP enable users to better understand what protocol was used, by whom, on which samples, and when. This comprehensive digital documentation and trackability help ensure experimental reproducibility in the scientific research fields.

“Scientific research faces challenges with experimental reproducibility, and having tools to combat them is a top priority,” said Zareh Zurabyan, Head of eLabNext, Americas. 

“Integrating the protocols.io platform with our Digital Lab Platform puts reproducible protocols at each user’s fingertips, allowing researchers to conduct more reproducible and trustworthy science. We are excited to further this goal with the protocols.io team.”

With the integration of the protocols.io add-on, eLabNext users can access comprehensive, step-by-step protocols directly from their protocols.io account. In addition, the integration allows users to search a library of private and public protocols, which can be easily imported into their DLP.

“From our first meeting with eLabNext to discuss integration options, it was clear that we share the same mission and approach to serving the research community,” explains Lenny Teytelman, Founder and President at protocols.io. 

“As we strive to encourage and support collaboration among researchers, it is essential that the tool makers collaborate as well. Working with the eLabNext team is a pleasure!” 

To learn more about eLabNext’s DLP and how to connect with the protocols.io add-on, visit the eLabMarketplace.

ENDS

AYLESBURY, UK. February 26th, 2025 – Amparo, a leader in direct-fit prosthetic sockets, has acquired Adapttech, a pioneer in smart prosthetic technology. This acquisition creates a combined entity poised to reshape the orthotics and prosthetics (O&P) industry.

The merger of both companies combines Amparo’s extensive experience in direct-fit socket technology and Adapttech’s cutting-edge advancements in data-driven prosthetic care. This synergy will lead to:

“This alliance unlocks incredible potential,” said Wesley Teerlink, CEO of Amparo. “We’re merging highly complementary technologies and building a powerhouse of innovation. The most exciting part is uniting our talented teams – I see a phenomenal future for the combined company.”

Frederico Carpinteiro, CEO of Adapttech, echoed this sentiment. He said: “We’re thrilled to join Amparo and its exceptional team. This deal presents tremendous growth opportunities and allows us to reach more people faster, significantly amplifying the impact of our technologies. I eagerly anticipate this new chapter and all it holds.”

Amparo will continue offering its full range of direct-fit sockets. Additionally, the expanded product portfolio will now include Adapttech’s innovative Motio Functional Reports, empowering patients with advanced data-driven prosthetic care.

ENDS

BOSTON, MA. February 24th, 2025 – Elemental Machines and eLabNext announced today that the Elemental Machines’ Connector add-on will now be available for free in the eLabMarketplace, eLabNext’s application library for extending and personalizing the functionality of their Digital Lab Platform. The Elemental Machines’ Connector supports wireless Elemental Machine sensors, which can monitor and record real-time data on temperature, humidity, and other environmental factors, allowing labs to respond instantly to temperature deviations among storage devices with customizable cellular alerts. 

“We are proud to continue partnering with eLabNext and serving customers worldwide,” says Ed Seguine, CEO of Elemental Machines. “With the launch of our new Elemental Machines’ Connector add-on, we’re showcasing our long-term vision and commitment to this partnership. This release not only supports our existing customers but offers new customers the chance to experience the value of the integration. By merging insights from Elemental Machines with eLabNext, users can gain a deeper, more sophisticated understanding of samples before and during scientific processes.”

The integration also gives users full visibility into equipment status and sample storage, driving informed decision-making, better resource management, greater reproducibility and compliance, and enhanced lab workflows. The Elemental Machines’ Connector automatically captures, documents, and provides access to data through cellular networks on a variety of environmental factors for audits and reviews to improve experimental accuracy.

“Centralizing lab data is one of the core missions of our Digital Lab Platform,” explains Zareh Zurabyan, Head of eLabNext, Americas. “The Elemental Machines’ Connector opens up eLabNext software to collect environmental data generated by lab equipment, giving users easy access to all temperature readings, including the duration and magnitude of deviations. Whether you are doing clinical work, R&D, diagnostics, or long-term biobanking, it is important to have insight into sample integrity, which generates terabytes of data using a range of equipment. This integration allows users to collect historical data on temperature deviations across the entire sample journey through the lab, giving them more confidence in their sample data.”

The Element-T sensors are capable of continuously monitoring and transmitting temperature data from freezers, refrigerators, and lab spaces. Download the Elemental Machines’ Connector for eLabNext from the eLabMarketplace and start integrating real-time data into your lab operations today.

Furthering its commitment to Enterprise Imaging in healthcare 

WOBURN, MA. 19th February, 2025 – BridgeHead Software, a leading provider of healthcare data management solutions, is thrilled to announce its membership with the Society for Imaging Informatics in Medicine (SIIM). SIIM is an international community of Imaging Informaticists united by their curiosity and commitment to advancing medical imaging through innovation, research, and education. This membership marks an exciting milestone in BridgeHead’s journey to support the global healthcare community with cutting-edge solutions that enhance imaging workflows, foster interoperability, and improve patient outcomes.

 

As a community, SIIM brings together scientists, developers, vendors, imaging IT experts, and clinicians from around the world to tackle the challenges associated with medical imaging. By joining SIIM, BridgeHead Software aims to collaborate with industry leaders, share expertise, and contribute to the development of next-generation imaging informatics solutions.

 

For over 30 years, BridgeHead Software has dedicated itself to pioneering solutions that address real-world data management issues for healthcare providers and clinical networks. Its award-winning, interoperable Clinical Data Repository (CDR), HealthStore®, augments systems such as EHR, PACS, LIMS, RIS, and more; by breaking down departmental and organizational data silos, and bringing together live and legacy data from across the healthcare ecosystem to provide a rich, longitudinal patient record.

 

The strength of HealthStore comes from its support for industry standards, such as FHIR; which enables it to aggregate a wide array of patient data spanning medical images, clinical reports, lab results, scanned documents and other essential clinical information; and making it available to clinicians to better support care decisions and improve patient outcomes. This data can be accessed via the EHR or other primary systems to streamline clinical workflows and increase productivity – supporting frontline clinical services as well as secondary uses, such as research and innovation in medical imaging.

 

Cheryl Kreider Carey, MBA, CAE, Chief Executive Officer at SIIM, welcomed the announcement: “We are delighted to have BridgeHead Software join the SIIM community. Their expertise in healthcare data management aligns perfectly with our mission to advance medical imaging through innovation and collaboration. We look forward to the insights and contributions BridgeHead will bring to our community as we work together to shape the future of imaging informatics.”

 

Jim Beagle, President and CEO at BridgeHead Software, commented: “Joining SIIM provides BridgeHead with an incredible platform to collaborate with a global network of innovators in imaging informatics. SIIM’s dedication to research, education, and advancing technology resonates with our mission to empower healthcare providers with solutions that enhance clinical efficiency, reduce operational risk, and improve patient care. We are excited to actively participate and contribute to the SIIM community.”

 

The SIIM membership underscores BridgeHead Software’s dedication to pushing the boundaries of medical imaging technology and supporting healthcare providers worldwide in their digital transformation journeys.

 

For more information about BridgeHead Software and its solutions, visit www.bridgeheadsoftware.com. 

BOSTON, MA. January 30th, 2025 — In a groundbreaking move set to transform the way scientific research is captured and managed, Boston-based SciShield, and Groningen, Netherlands-based eLabNext, have merged to launch the world’s first and only Scientific Management Platform (SMP). The combined company has been re-branded as SciSure. Founded by scientists for scientists, SciSure delivers the unique combination of eLabNext’s Digital Lab Platform with its ELN (Electronic Laboratory Notebook) and LIMS (Laboratory Information Management System) and SciShield’s comprehensive, trusted, and compliant EHS (Environmental Health & Safety) platform. The SMP will address the most pressing issues in science today: fragmented systems and the inefficiencies they create.  
 
“Scientific organizations face the costly challenge of maintaining disparate systems that burden scientists and add unnecessary cost, complexity, and risk. Today, that changes,” said Phil Meer, Chief Executive Officer. “By bringing eLabNext and SciShield together, we accelerate our vision to deliver an unparalleled scientist experience via a platform that will serve as a digital ecosystem for stakeholders vested in ensuring accurate, safe, compliant, and streamlined scientific research.”

Unparalleled Global Scale

Trust, protection, and research integrity form the core values of SciSure. The combined company offers unparalleled global scale, featuring 800+ unique customer organizations, 550,000+ research and administrative users, and 37,000+ lab groups across Europe, North America, Asia, and Australia. Customers include global Fortune 100 Biopharma organizations, over one-third of United States R1 Academic Institutions, and laboratories within companies across diverse industries, including healthcare, oil & gas, and food safety.
 
Research, Safety, Training, and Operations in a Single Platform

For decades, scientists, Lab Operations, Facilities Management, and EHS professionals have managed the dynamic and complex operational and regulatory requirements that span scientific organizations using fragmented technologies. These disconnected systems aren’t just inconvenient—they create significant risks. These risks include inadequate research documentation, poor IP management, loss of critical experiment data, lapses in training, compliance violations, and the mishandling of hazardous materials. The SMP mitigates these risks by creating synchronized, intelligent, and proactive data-driven insights and seamless, secure workflows to enable scientists to effectively conduct and document their research, and scientific organizations to proactively inspect, report, remediate, and, ultimately, minimize risk. Moreover, via its partner-enabled Marketplace, SciSure offers an open digital ecosystem designed for internal customer systems and third-party software vendors to seamlessly deliver third-party data and workflows into and out of the Scientific Management Platform (SMP).

“Our mission is to support scientific organizations in facilitating unburdened, uncompromised, and safe scientific advancement,” said Nathan Watson, SciShield Founder and SciSure Chief Strategy Officer. “The SMP enables fast, efficient, and more reliable decision-making, allowing scientists to focus on what they do best: advancing their scientific discoveries.”
 
A Solution Designed by Scientists, for Scientists

With scientists and researchers at the core of SciSure’s Senior Leadership Team, the Scientific Management Platform (SMP) will improve the scientist experience, with benefits including:
 
– Liberating scientists from administrative and compliance burdens
– Enhancing trust in digital solutions and accuracy of data
– Establishing a home base for planning, documenting, and organizing research data
– Streamlining and organizing multiple technologies, allowing for data from adjacent systems to be securely integrated and available to scientists within their daily workflow
 
“Scientists must have confidence and trust in the digital solutions they use. When trust goes up, speed and innovation follow,” said Erwin Seinen, eLabNext co-founder and SciSure Chief Revenue Officer. “The SMP is the ultimate home base for scientists, lab operations, and EHS professionals to thrive together,” added Wouter de Jong, eLabNext co-founder and SciSure Chief Product Officer.

Ownership

SciSure is backed by Strattam Capital. Strattam Capital first invested in SciShield in 2023 to enable the company to accelerate its pace of innovation while continuing to provide best-in-class services to its high-profile customer base. In addition, the investment provided SciShield with resources to expand its product offerings, operations, and sales teams.
 
About the SMP

The Scientific Management Platform (SMP) redefines laboratory efficiency and compliance, empowering organizations to deliver on their missions without compromise. By uniting critical systems, the SMP champions a new era of trust and innovation in digital science, fostering collaboration and liberating scientists and researchers to make the breakthroughs the world is counting on them to make.

Explore more about the SciSure vision and learn how we’re reimagining the Scientist Experience at www.scisure.com.
 
For more information, please contact:
Jon Zibell
Vice President of Global Alliances & Marketing
Jon.Zibell@scisure.com

NOTTINGHAM, UK. January 28th, 2025 – Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing facility in Nottingham, UK.

The new facility is in addition to its existing 50,000 sq. ft facility, Trent Gateway, and the purpose-built facility has been designed specifically in line with the revised EU GMP Annex-1 regulations. The 7,000 sq. ft facility will support the manufacturing of aseptic and terminally sterilised small volume liquids and powders for parenteral, nasal and pulmonary delivery.

The new facility has the capability to support formulation development, clinical manufacture and analytical testing, with batch sizes of up to 2,000 vials, pre-filled syringes and pre-filled cartridges for liquid formulations and pre-sterilized powders.

The expansion is a natural progression for Upperton which already develops and manufactures small molecule and biological, non-sterile, oral, nasal and pulmonary dosage forms from early development to late-stage clinical manufacture for global biotech and pharmaceutical companies. 

Nikki Whitfield, Chief Executive Officer at Upperton, said: “We are delighted to complete the build of our sterile facility. The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.”

The sterile facility will feature two cleanrooms with advanced VHP isolation technology and carry out GMP manufacturing of sterile drug products making use of existing full-service formulation development and quality control laboratories.

Jon Austwick, Director of Quality and Compliance at Upperton, said: “This expansion illustrates our continued investment in our capabilities to support drug developers to scale and accelerate the path to delivering safe and effective medicines to patients. The facility has been built with the highest level of quality and is a testament to our internal teams and build vendor who have worked tirelessly over the past 12 months to bring our vision to life.” 

This investment in sterile drug product manufacturing enhances the existing service offering from Upperton, which provides formulation development across a broad range of dosage forms, clinical trial supply, and late-stage manufacturing for non-sterile dosage forms for both small molecules and biologics.

Whilst the commissioning of the facility, along with the installation and validation of new equipment continues, Upperton will utilise existing expertise within its research and development and analytical teams to support the pre-formulation and stability studies for early proof-of-concept products for parenteral, nasal and pulmonary delivery. 

ENDS

ARIZONA, USA. 6th January, 2024 – Erectile dysfunction (ED) affects approximately 30 million men in the United States, yet stigma and misinformation keep it a silent epidemic. Thanks to advancements in treatment options and accessibility, men now have the tools to reclaim their sexual wellness, boost confidence, and enhance their overall quality of life.

ED is more than a physical condition—it profoundly impacts mental health, relationships, and self-esteem. Studies reveal that nearly 52% of men experience some form of ED during their lifetime, with the prevalence increasing with age. However, embarrassment and misconceptions prevent many from seeking help, leaving only 25% of affected individuals pursuing treatment.

 

“Erectile dysfunction doesn’t just affect intimacy; it creates a ripple effect that can harm relationships and mental health. Addressing it is not just about sexual performance; it’s about restoring a sense of self-worth and overall well-being,” said Dr. John Stevens, a leading urologist and advocate for men’s health.

Edrugstore.com, a leading online pharmacy, is transforming how ED treatment is accessed. Offering FDA-approved medications and discreet consultation services, the platform empowers men to seek help from the comfort of their homes. Licensed healthcare professionals provide personalized prescriptions, with medications delivered directly to patients’ doorsteps.

 

“Our mission is to make ED treatment accessible and stigma-free,” said Jim a representative of Edrugstore.com. 

 

“We’ve witnessed countless men regain their confidence and rebuild their relationships through our services.”

Breaking down the barriers of silence, Edrugstore.com has partnered with health educators to spread awareness about ED causes, treatments, and the importance of early intervention. These initiatives aim to normalize conversations about ED, encouraging men to take control of their health.

 

Recent statistics underscore the life-changing impact of treatment:

David, a 48-year-old software engineer from Chicago, avoided social interactions and suffered in silence for over a year. After consulting with Edrugstore.com, he began a personalized treatment plan that revitalized his life.

“I feel like myself again,” David shared. “My relationships are stronger, and I no longer feel defined by my condition.”

 

As awareness grows, experts emphasize that addressing ED goes beyond physical health—it’s about empowering men to prioritize their overall well-being.

“At Edrugstore.com, we’re not just offering medications; we’re creating pathways for men to regain their confidence and thrive,” added Jim

Edrugstore.com is a trusted leader in online pharmaceutical services specializing in men’s health and wellness. For over 20 Years, the company has prioritized accessibility, privacy, and education to help men address sensitive health concerns discreetly and effectively. With a strong commitment to innovation and customer satisfaction, Edrugstore.com empowers individuals to take charge of their health and live life to the fullest.

For more information, visit www.edrugstore.com or explore their blog.